Assembly Biosciences (Assembly Biosciences) Long-Term Capital Lease Obligation : $1.12 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Assembly Biosciences Long-Term Capital Lease Obligation?

Assembly Biosciences's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.12 Mil.

Assembly Biosciences's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($0.06 Mil) to Sep. 2023 ($0.05 Mil) but then increased from Sep. 2023 ($0.05 Mil) to Dec. 2023 ($1.12 Mil).

Assembly Biosciences's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($3.33 Mil) to Dec. 2022 ($0.10 Mil) but then increased from Dec. 2022 ($0.10 Mil) to Dec. 2023 ($1.12 Mil).

Assembly Biosciences Long-Term Capital Lease Obligation Historical Data

The historical data trend for Assembly Biosciences's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Long-Term Capital Lease Obligation Chart

Assembly Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

9.08

6.73

3.33

0.10

1.12

Assembly Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.10	0.08	0.06	0.05	1.12

Assembly Biosciences (NAS:ASMB) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Assembly Biosciences Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Assembly Biosciences (Assembly Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (NAS:ASMB) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

V7B1:Germany

Address

331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080

Website

https://www.assemblybio.com

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Executives

Alexander Schornstein	10 percent owner	KAISER-FRIEDRICH-ALLEE 2, AACHEN 2M 52074
Nicole S White	officer: Chief Manufacturing Officer	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Gilead Sciences Inc	10 percent owner	333 LAKESIDE DR, FOSTER CITY CA 94404
Jason A Okazaki	officer: Chief Legal & Business Officer	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Delaney William E Iv	officer: CSO, Virology	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Jeanette M Bjorkquist	officer: Principal Accounting Officer	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
John G Mchutchison	director, officer: CEO and President	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Michael P. Samar	officer: See Remarks	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST. SUITE 310, CARMEL IN 46032
Luisa M Stamm	officer: Chief Medical Officer	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN ST, SUITE 310, CARMEL IN 46032
Michael Houghton	director	C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA 94080
Lisa Johnson-pratt	director	C/O TRACON PHARMACEUTICALS, INC., 4350 LA JOLLA VILLAGE DRIVE, SUITE 800, SAN DIEGO CA 92122
Jacqueline Sybil Papkoff	officer: See remarks	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N. MERIDIAN STREET, SUITE 310, CARMEL IN 46032
Gina Consylman	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Richard James Colonno	officer: Chief Science Officer	ASSEMBLY BIOSCIENCES, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Thomas Joseph Russo	officer: CFO	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032